|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.02.26 - 22:09
|
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--$GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 41,852 shares of its common stock to 88 new non-executive employees and one non-qualified stock option award to purchase 4,965 shares of its common stock to one new non-executive employee with a grant date of February 23, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such in...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.02.26 - 22:06
|
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook (Business Wire)
|
|
|
Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening
Expects full year 2026 total revenue to grow in the range of 27% to 30% year-over-yearPALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025.
Fourth Quarter 2025 Financial Highlights
For the three-month period ended December 31, 2025, as compared to the same period of 2024:
Reported total revenue of $281.3 million, an increase of 39%, driven by:
Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests, an increase of 38%
Biopharma & Data revenue of $54.0 million, an increase of 9%
Screening revenue of $35.1 million, and approximately 38,000 Shield screening tests, compared to 6,400 tests in the prior year period
Generated non-GAAP gross margin of 66%, compared to 63% for the fourth quarter of 2024
Full Year 2025 Financia...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
